查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2030年造血干细胞移植的市场预测：按移植类型、适应症、用途、最终用户和地区进行全球分析
市场调查报告书
商品编码
1372011

2030年造血干细胞移植的市场预测：按移植类型、适应症、用途、最终用户和地区进行全球分析

Hematopoietic Stem Cell Transplantation Market Forecasts to 2030 - Global Analysis By Transplant Type, By Disease Indication, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球造血干细胞移植（HSCT）市场规模为 28.9 亿美元，预计在预测期内将以 11.3% 的年复合成长率增长，到 2030 年达到 61.2 亿美元。

在称为造血干细胞移植（HSCT）（也称为骨髓移植）的医疗程序中，将造血干细胞移植到患者体内以替换或修復受损或功能障碍的骨髓。红血球、白血球和血小板都是由造血干细胞产生的。造血干细胞是具有这种特殊能力的多功能细胞。

根据白血病和淋巴瘤协会（LLS）2021年发布的资料，预计2021年将有约61,090人被诊断出罹患白血病。

癌症患病增加

由于对尖端治疗方案的需求，癌症罹患率的上升是造血干细胞移植（HSCT）的主要市场促进因素。造血干细胞移植是治疗方法。随着造血干细胞移植的需求增加，癌症罹患率不断增加，推动了市场的成长。这个过程涉及用受损或癌症的造血细胞替换不健康的干细胞，并且可以治癒某些癌症。因此，癌症患者数量的增加正在推动造血干细胞移植市场的发展，也是刺激该领域研究和开发的主要要素。

昂贵的移植手术

与整个移植手术相关的费用，包括移植前评估、移植手术本身和移植后护理，可能会令人望而却步。对很大一部分人来说，这种经济负担往往限制了造血干细胞移植作为治疗选择的可近性并影响其接受度。此外，它也为保险公司和医疗保健系统带来了挑战，阻碍了造血干细胞移植的广泛应用和采用。因此，造血干细胞移植（HSCT）手术的高成本严重限制了市场。

医疗健康领域投资

随着医疗保健产业投资的增加，造血干细胞移植市场蕴藏着巨大的商机。许多地方政府部门也提供资金和投资来发展当地的医疗保健系统。为了支持干细胞疗法和再生医学的研究，美国国立卫生研究院 (NIH) 于 2019 年宣布津贴2,900 万美元。这笔津贴授予了正在利用干细胞开发针对多种疾病的新治疗方法的美国研究人员。这将使更多患者受益于这种挽救生命的治疗方法，增加的投资也将支持专业移植中心的发展，改善获得尖端护理的机会并促进创新。

造血干细胞移植的不良反应

造血干细胞移植市场的扩张受到阻碍，不仅因为移植物抗宿主疾病的严重併发症，还因为调理方案对消化器官系统、口腔、心臟和身体部位等器官和身体部位的负面影响。肺部。预计移植物抗宿主疾病（GVHD）是移植物将患者的健康细胞（宿主）误认为是外来入侵者并对其进行攻击和破坏的疾病。此外，即使患者和捐赠者的HLA相近，GVHD的风险也会降低，但并不能完全消除。根据具体情况，它甚至可能是致命的。预计市场将因此类事件而下跌。

COVID-19 的影响：

造血干细胞移植 (HSCT) 市场受到 COVID-19大流行的严重影响。医疗保健资源的分配最初会扰乱移植计划，并可能延迟挽救生命的治疗。然而，这场危机凸显了医疗创新和研究的重要性，可能会激发更多资金和对造血干细胞移植作为尖端治疗方法的兴趣。在物流方面，供应链中断减少了移植必需品的供应。远端医疗在移植前和移植后护理中也变得普及。大流行的长期影响可能需要进行调整，以确保免疫抑制患者的安全，这可能会重塑市场。

预计自体移植领域在预测期内将是最大的。

在预测期内，造血干细胞移植市场预计将由自体移植部门主导。自体骨髓移植涉及将从患者采集的精製骨髓进行回输。根据国际血液和骨髓移植研究中心（CIBMTR）2020年报告，2013年美国年度异体移植受者数量超过8000例，预计2019年将有9498例移植，高于2018年的9509例。 。自2000年以来，美国自体移植患者数量稳定成长，2019年达到14,270人。在美国，超过 60% 的移植活动仍是自体移植。所有这些要素都有助于该细分市场的扩张。

骨髓移植（BMT）预计在预测期内年复合成长率

预计骨髓移植领域将在预测期内快速成长。为了取代无法产生足够健康血球的骨髓，在骨髓移植过程中将健康的造血干细胞注入体内。骨髓功能障碍或耗竭的患者可以透过骨髓移植获得健康的造血干细胞。预计该领域的成长将受到研发力度加大的推动。此外，公共和私人对骨髓移植支持的增加预计将刺激该领域的成长。

占比最高的地区

北美造血干细胞移植（HSCT）市场预计将占据主要份额。该地区的发展主要受到白血病患者增加以及公共和私人研发投资增加等要素的推动。美国癌症研究所的资料显示，2020年，白血病占美国新发癌症病例的3.2%，占癌症死亡人数的3.9%。例如，2019 年 12 月，国家眼科研究所的研究人员开始进行一项临床试验，调查一种新型患者特异性干细胞疗法治疗地理萎缩的安全性。因此，白血病患者数量的增加预计将增加造血干细胞移植的需求，从而推动该领域的市场成长。

复合年复合成长率最高的地区：

由于许多重要要素，亚太地区的造血干细胞移植（HSCT）市场正在迅速扩张。人口老化的加剧和血液疾病的流行推动了造血干细胞移植的需求。由于印度、中国和韩国等国家医疗保健基础设施和医疗旅游业的改善，该地区正在成为造血干细胞移植的中心。此外，由于与国际医疗保健提供者和研究机构的合作，亚太地区是造血干细胞移植服务和技术的一个充满前景的市场。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和年复合成长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第1章执行摘要

第2章前言

  • 概述
  • 利害关係人
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第3章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第5章全球造血干细胞移植（HSCT）市场：依移植类型

  • 同种异体的
  • 自体的
  • 其他类型的移植

第6章全球造血干细胞移植（HSCT）市场：依疾病适应症

  • 淋巴组织增生性疾病
    • 霍奇金淋巴瘤
    • 浆细胞紊乱
    • 其他淋巴组织增生性疾病
  • 非恶性疾病
    • 骨髓衰竭
    • 血红素疾病
    • 自体免疫疾病
    • 其他非恶性疾病
  • 白血病
    • 急性淋巴性白血病
    • 急性骨髓性白血病
    • 骨髓发育不良症候群（MDS）
    • 其他白血病
  • 其他疾病的适应症

第7章全球造血干细胞移植（HSCT）市场：依应用分类

  • 骨髓移植（BMT）
  • 週边血干细胞移植（PBSCT）
  • 脐带血移植（CBT）
  • 其他用途

第8章全球造血干细胞移植 (HSCT) 市场：按最终用户分类

  • 医院
  • 专科诊所
  • 其他最终用户

第9章全球造血干细胞移植（HSCT）市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第10章进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第11章公司简介

  • AllCells Corp.
  • Athersys Inc.
  • Beike Biotechnology Co. Ltd.
  • bluebird bio Inc.
  • Cellular Biomedicine Group Inc.
  • Gamida Cell Ltd.
  • Lonza Group Ltd.
  • MEDIPOST Co. Ltd.
  • Merck KGaA
  • Mesoblast Ltd.
  • Pluristem Therapeutics Inc.
  • Sanofi SA
  • Sartorius CellGenix GmbH
  • ScienCell Research Laboratories, Inc.
  • STEMCELL Technologies, Inc.
  • Taiga Biotechnologies Inc.
  • Takeda Pharmaceutical Co. Ltd.
  • Talaris Therapeutics
  • Thermo Fisher Scientific
Product Code: SMRC24067

According to Stratistics MRC, the Global Hematopoietic Stem Cell Transplantation (HSCT) Market is accounted for $2.89 billion in 2023 and is expected to reach $6.12 billion by 2030 growing at a CAGR of 11.3% during the forecast period. Hematopoietic stem cells are transplanted into a patient during a medical procedure known as hematopoietic stem cell transplantation (HSCT), also referred to as bone marrow transplantation, in order to replace or repair their damaged or dysfunctional bone marrow. Red blood cells, white blood cells, and platelets can all be produced by hematopoietic stem cells, which are multipotent cells with this special ability.

According to the data published by the Leukemia & Lymphoma Society (LLS) in 2021, around 61,090 people were estimated to be diagnosed with leukemia 2021.

Market Dynamics:

Driver:

Increasing prevalence of cancer

Due to the demand for cutting-edge treatment options, the rising incidence of cancer is a significant market driver for hematopoietic stem cell transplantation (HSCT). For patients with different types of blood cancers and hematological disorders, HSCT is an essential treatment. Cancer incidence increases along with the demand for HSCT procedures, which propels market growth. This procedure involves swapping out unhealthy stem cells for damaged or cancerous blood-forming cells, potentially curing some forms of cancer. As a result, the growing number of cancer patients is a major factor in boosting the market for HSCT and stimulating research and development in the area.

Restraint:

Expensive transplantation procedures

The costs associated with the entire transplant procedure, including pre-transplant assessments, the transplant procedure itself, and post-transplant care, can be exorbitant. For a sizeable portion of the population, this financial burden frequently restricts accessibility, which has an effect on the acceptance of HSCT as a treatment option. Additionally, it creates difficulties for insurance companies and healthcare systems, which prevents HSCT from being used and adopted more widely. As a result, the market is significantly constrained by the high cost of hematopoietic stem cell transplantation (HSCT) procedures.

Opportunity:

Investment in healthcare sector

Due to the rising investment in the healthcare industry, the hematopoietic stem cell transplantation market has a sizable opportunity. The government sector in many regions also contributes money and investments to advance the local healthcare system. In order to support research in stem cell therapy and regenerative medicine, the National Institutes of Health (NIH) announced a grant worth USD 29 million in 2019. The grant was given to US researchers that are using stem cells to create novel treatments for a number of diseases. It ensures that more patients can benefit from this life-saving therapy is created by increased investment, which also supports the development of specialized transplant centers, improves access to cutting-edge care, and fosters innovation.

Threat:

Adverse impacts of hematopoietic stem cell transplantation

The negative effects of hematopoietic stem cell transplantation on organs and body parts, including the gastrointestinal system, mouth, heart, and lungs, associated with the conditioning regimen and others, as well as the serious complication of graft vs. host disease, are anticipated to hinder the market's expansion. Both regular allogeneic stem cell transplants and reduced-intensity allogeneic stem cell transplants can result in graft-versus-host disease (GVHD), in which the graft mistakes the patient's healthy cells (the host) for foreign invaders and attacks and destroys them. Moreover, even a close HLA match between the patient and donor lowers but does not completely eliminate the risk of GVHD. It might even be fatal in some circumstances. As a result of such events, the market is expected to decline.

COVID-19 Impact:

The hematopoietic stem cell transplantation (HSCT) market was significantly impacted by the COVID-19 pandemic. Due to the allocation of healthcare resources, it initially disrupted transplant schedules, potentially delaying life-saving procedures. However, the crisis highlighted the significance of medical innovation and research, potentially spurring more funding and interest in HSCT as a cutting-edge therapy. Logistics were impacted by supply chain disruptions that reduced the supply of vital transplant supplies. Telemedicine has become more popular for pre- and post-transplant care as well. The long-term effects of the pandemic may require adjustments to ensure the safety of immunosuppressed patients, which could potentially reshape the market.

The autologous segment is expected to be the largest during the forecast period

During the anticipated period, the market for hematopoietic stem cell transplantation is anticipated to be dominated by the autologous transplantation segment. Following purification procedures, autologous bone marrow products are taken from the patient and reinfused. Allogeneic transplant recipients in the US exceeded 8,000 per year in 2013, and 9,498 transplants are anticipated in 2019, up from 9,509 in 2018, according to the Center for International Blood and Marrow Transplant Research's (CIBMTR) 2020 report. Since 2000, the number of autologous transplant recipients in the US has increased steadily, reaching 14,270 in 2019. Over 60% of transplant activity in the US still involves autologous transplants. All of these factors contribute to the segment expansion.

The bone marrow transplant (BMT) segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the bone marrow transplant segment is anticipated to grow at a rapid pace. In order to replace bone marrow that does not produce enough healthy blood cells, healthy blood-forming stem cells are injected into the body during a bone marrow transplant procedure. Patients with dysfunctional or depleted bone marrow can receive healthy hematopoietic stem cells through a bone marrow transplant. Growth in the segment is anticipated to be boosted by rising research and development efforts. Additionally, it is anticipated that rising supportive actions by the public and private sectors toward bone marrow transplants will spur segment growth.

Region with largest share:

The market for hematopoietic stem cell transplantation (HSCT) in North America is expected to witness significant market share. The region is being driven primarily by factors like the rise in leukemia cases and rising public and private sector investment in research and development. Leukemia accounted for 3.2% of all new cancer cases and 3.9% of all cancer deaths in the US in 2020, according to data from the National Cancer Institute. For instance, the National Eye Institute's researchers began a clinical trial in December 2019 to examine the safety of a novel patient-specific stem cell-based therapy for the treatment of geographic atrophy. Therefore, it is anticipated that rising leukemia cases will increase demand for hematopoietic stem cell transplantation, driving up market growth in the area.

Region with highest CAGR:

Due to a number of crucial factors, the hematopoietic stem cell transplantation (HSCT) market in the Asia-Pacific region is expanding rapidly. The demand for HSCT procedures is being driven by the rising geriatric population and the prevalence of hematological disorders. The region is becoming a hub for HSCT as a result of improvements in healthcare infrastructure and medical tourism in nations like India, China, and South Korea. Furthermore, Asia Pacific is a promising market for HSCT services and technologies due to collaborations with international healthcare providers and research organizations.

Key players in the market:

Some of the key players in Hematopoietic Stem Cell Transplantation (HSCT) market include: AllCells Corp., Athersys Inc., Beike Biotechnology Co. Ltd., bluebird bio Inc., Cellular Biomedicine Group Inc., Gamida Cell Ltd., Lonza Group Ltd., MEDIPOST Co. Ltd., Merck KGaA, Mesoblast Ltd., Pluristem Therapeutics Inc., Sanofi SA, Sartorius CellGenix GmbH, ScienCell Research Laboratories, Inc., STEMCELL Technologies, Inc., Taiga Biotechnologies Inc., Takeda Pharmaceutical Co. Ltd., Talaris Therapeutics and Thermo Fisher Scientific.

Key Developments:

In June 2023, Kindred Group plc, a company that offers online services, launched a new campaign with Matchis, the Dutch Centre for Stem Cell Donors, to generate more awareness for stem cell transplantation and the shortage of donors.

In January 2023, Jasper Therapeutics, Inc., announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has granted orphan drug designation to briquilimab (formerly known as JSP191), a monoclonal antibody targeting the CD117 (stem cell factor) receptor, for conditioning treatment prior to HCT. Previously, the U.S. Food and Drug Administration granted orphan drug designation to briquilimab in HCT, as well as rare pediatric disease designation for the treatment of severe combined immunodeficiency (SCID).

In June 2022, Veloxis Pharmaceuticals, a specialty pharmaceutical company, announced the dosing of the first patient by its partner, Xenikos B.V., a privately held biotechnology company, in a pivotal Phase 3 clinical study [NCT04934670] designed to evaluate T-Guard versus ruxolitinib for the treatment of patients with Grade III or IV steroid-refractory acute graft-versus-host disease (SR-aGVHD) following allogeneic hematopoietic stem cell transplant (allo-HSCT). T-Guard is currently being developed by Xenikos B.V.

Transplant Types Covered:

  • Allogeneic
  • Autologous
  • Other Transplant Types

Disease Indications Covered:

  • Lymphoproliferative Disorders
  • Non-malignant Disorders
  • Leukemia
  • Other Disease Indications

Applications Covered:

  • Bone Marrow Transplant (BMT)
  • Peripheral Blood Stem Cells Transplant (PBSCT)
  • Cord Blood Transplant (CBT)
  • Other Applications

End Users Covered:

  • Hospitals
  • Specialty Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Transplant Type

  • 5.1 Introduction
  • 5.2 Allogeneic
  • 5.3 Autologous
  • 5.4 Other Transplant Types

6 Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Disease Indication

  • 6.1 Introduction
  • 6.2 Lymphoproliferative Disorders
    • 6.2.1 Hodgkin lymphoma
    • 6.2.2 Plasma Cell Disorders
    • 6.2.3 Other Lymphoproliferative Disorders
  • 6.3 Non-malignant Disorders
    • 6.3.1 Bone Marrow Failure
    • 6.3.2 Hemoglobinopathies
    • 6.3.3 Autoimmune Disease
    • 6.3.4 Others Non-malignant Disorders
  • 6.4 Leukemia
    • 6.4.1 Acute Lymphatic Leukemia
    • 6.4.2 Acute Myeloid Leukemia
    • 6.4.3 Myelodysplastic Syndrome (MDS)
    • 6.4.4 Other Leukemia
  • 6.5 Other Disease Indications

7 Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Application

  • 7.1 Introduction
  • 7.2 Bone Marrow Transplant (BMT)
  • 7.3 Peripheral Blood Stem Cells Transplant (PBSCT)
  • 7.4 Cord Blood Transplant (CBT)
  • 7.5 Other Applications

8 Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals
  • 8.3 Specialty Clinics
  • 8.4 Other End Users

9 Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 AllCells Corp.
  • 11.2 Athersys Inc.
  • 11.3 Beike Biotechnology Co. Ltd.
  • 11.4 bluebird bio Inc.
  • 11.5 Cellular Biomedicine Group Inc.
  • 11.6 Gamida Cell Ltd.
  • 11.7 Lonza Group Ltd.
  • 11.8 MEDIPOST Co. Ltd.
  • 11.9 Merck KGaA
  • 11.10 Mesoblast Ltd.
  • 11.11 Pluristem Therapeutics Inc.
  • 11.12 Sanofi SA
  • 11.13 Sartorius CellGenix GmbH
  • 11.14 ScienCell Research Laboratories, Inc.
  • 11.15 STEMCELL Technologies, Inc.
  • 11.16 Taiga Biotechnologies Inc.
  • 11.17 Takeda Pharmaceutical Co. Ltd.
  • 11.18 Talaris Therapeutics
  • 11.19 Thermo Fisher Scientific

List of Tables

  • Table 1 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Transplant Type (2021-2030) ($MN)
  • Table 3 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Allogeneic (2021-2030) ($MN)
  • Table 4 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Autologous (2021-2030) ($MN)
  • Table 5 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Other Transplant Types (2021-2030) ($MN)
  • Table 6 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Disease Indication (2021-2030) ($MN)
  • Table 7 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Lymphoproliferative Disorders (2021-2030) ($MN)
  • Table 8 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Hodgkin lymphoma (2021-2030) ($MN)
  • Table 9 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Plasma Cell Disorders (2021-2030) ($MN)
  • Table 10 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Other Lymphoproliferative Disorders (2021-2030) ($MN)
  • Table 11 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Non-malignant Disorders (2021-2030) ($MN)
  • Table 12 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Bone Marrow Failure (2021-2030) ($MN)
  • Table 13 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Hemoglobinopathies (2021-2030) ($MN)
  • Table 14 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Autoimmune Disease (2021-2030) ($MN)
  • Table 15 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Others Non-malignant Disorders (2021-2030) ($MN)
  • Table 16 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Leukemia (2021-2030) ($MN)
  • Table 17 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Acute Lymphatic Leukemia (2021-2030) ($MN)
  • Table 18 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Acute Myeloid Leukemia (2021-2030) ($MN)
  • Table 19 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Myelodysplastic Syndrome (MDS) (2021-2030) ($MN)
  • Table 20 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Other Leukemia (2021-2030) ($MN)
  • Table 21 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Other Disease Indications (2021-2030) ($MN)
  • Table 22 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Application (2021-2030) ($MN)
  • Table 23 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Bone Marrow Transplant (BMT) (2021-2030) ($MN)
  • Table 24 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Peripheral Blood Stem Cells Transplant (PBSCT) (2021-2030) ($MN)
  • Table 25 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Cord Blood Transplant (CBT) (2021-2030) ($MN)
  • Table 26 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 27 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By End User (2021-2030) ($MN)
  • Table 28 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 29 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 30 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.